Neuro-Oncology: An Emerging Neurologic Subspecialty in Thailand
Keywords:
Neuro-Oncology; Emerging; Neurologic; ThailandAbstract
No Abstract
References
1. Vaillant B, Kuo SH, de Groot J. Emerging subspecialties in neurology:
neuro-oncology: a developing subspecialty with many opportunities. Neurology.
2009 Mar;72(11):e51-3.
2. Sathornsumetee S, Reardon DA. High-grade astrocytoma. In: Norden AD,
Reardon DA, Wen PYC, ed. Primary central nervous system tumors:
Pathogenesis and therapy. New Jersey: Humana Press; 2011. p. 195-232.
3. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn
MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for
glioblastoma. N Engl J Med. 2005 Mar;352(10):987-96.
4. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer
RC, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide
versus radiotherapy alone on survival in glioblastoma in a randomised
phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet
Oncol. 2009 May;10(5):459-66.
5. Cancer Genome Atlas Research Network. Comprehensive genomic characterization
defines human glioblastoma genes and core pathways. Nature.
2008 Oct;455(7216):1061-8.
6. Sathornsumetee S, Rich JN. Antiangiogenic therapy in malignant glioma:
promise and challenge. Curr Pharm Des. 2007;13(35):3545-58.
7. Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE,
et al. Bevacizumab alone and in combination with irinotecan in recurrent
glioblastoma. J Clin Oncol. 2009 Oct;27(28):4733-40.
8. Kreisl TN, Kim L, Moore K, Duic P, Royce C, Stroud I, et al. Phase
II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan
at tumor progression in recurrent glioblastoma. J Clin Oncol. 2009
Feb;27(5):740-5.
9. Vredenburgh JJ, Desjardins A, Herndon JE 2nd, Marcello J, Reardon
DA, Quinn JA, et al. Bevacizumab plus irinotecan in recurrent glioblastoma
multiforme. J Clin Oncol. 2007 Oct;25(30):4722-9.
10. Sathornsumetee S, Cao Y, Marcello JE, Herndon JE 2nd, McLendon RE,
Desjardins A, et al. Tumor angiogenic and hypoxic profiles predict radiographic
response and survival in malignant astrocytoma patients treated
with bevacizumab and irinotecan. J Clin Oncol. 2008 Jan;26(2):271-8.
11. Platta CS, Khuntia D, Mehta MP, Suh JH. Current treatment strategies
for brain metastasis and complications from therapeutic techniques: a
review of current literature. Am J Clin Oncol. 2010 Aug;33(4):398-407.
12. Darnell RB, Posner JB. Paraneoplastic syndromes involving the nervous
system. N Engl J Med. 2003 Oct;349(16):1543-54.
13. McKeon A, Apiwattanakul M, Lachance DH, Lennon VA, Mandrekar
JN, Boeve BF, et al. Positron emission tomography-computed tomography
in paraneoplastic neurologic disorders: systematic analysis and review.
Arch Neurol. 2010 Mar;67(3):322-9.
14. Lancaster E, Martinez-Hernandez E, Dalmau J. Encephalitis and antibodies
to synaptic and neuronal cell surface proteins. Neurology. 2011 Jul;77(2):
179-89.
neuro-oncology: a developing subspecialty with many opportunities. Neurology.
2009 Mar;72(11):e51-3.
2. Sathornsumetee S, Reardon DA. High-grade astrocytoma. In: Norden AD,
Reardon DA, Wen PYC, ed. Primary central nervous system tumors:
Pathogenesis and therapy. New Jersey: Humana Press; 2011. p. 195-232.
3. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn
MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for
glioblastoma. N Engl J Med. 2005 Mar;352(10):987-96.
4. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer
RC, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide
versus radiotherapy alone on survival in glioblastoma in a randomised
phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet
Oncol. 2009 May;10(5):459-66.
5. Cancer Genome Atlas Research Network. Comprehensive genomic characterization
defines human glioblastoma genes and core pathways. Nature.
2008 Oct;455(7216):1061-8.
6. Sathornsumetee S, Rich JN. Antiangiogenic therapy in malignant glioma:
promise and challenge. Curr Pharm Des. 2007;13(35):3545-58.
7. Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE,
et al. Bevacizumab alone and in combination with irinotecan in recurrent
glioblastoma. J Clin Oncol. 2009 Oct;27(28):4733-40.
8. Kreisl TN, Kim L, Moore K, Duic P, Royce C, Stroud I, et al. Phase
II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan
at tumor progression in recurrent glioblastoma. J Clin Oncol. 2009
Feb;27(5):740-5.
9. Vredenburgh JJ, Desjardins A, Herndon JE 2nd, Marcello J, Reardon
DA, Quinn JA, et al. Bevacizumab plus irinotecan in recurrent glioblastoma
multiforme. J Clin Oncol. 2007 Oct;25(30):4722-9.
10. Sathornsumetee S, Cao Y, Marcello JE, Herndon JE 2nd, McLendon RE,
Desjardins A, et al. Tumor angiogenic and hypoxic profiles predict radiographic
response and survival in malignant astrocytoma patients treated
with bevacizumab and irinotecan. J Clin Oncol. 2008 Jan;26(2):271-8.
11. Platta CS, Khuntia D, Mehta MP, Suh JH. Current treatment strategies
for brain metastasis and complications from therapeutic techniques: a
review of current literature. Am J Clin Oncol. 2010 Aug;33(4):398-407.
12. Darnell RB, Posner JB. Paraneoplastic syndromes involving the nervous
system. N Engl J Med. 2003 Oct;349(16):1543-54.
13. McKeon A, Apiwattanakul M, Lachance DH, Lennon VA, Mandrekar
JN, Boeve BF, et al. Positron emission tomography-computed tomography
in paraneoplastic neurologic disorders: systematic analysis and review.
Arch Neurol. 2010 Mar;67(3):322-9.
14. Lancaster E, Martinez-Hernandez E, Dalmau J. Encephalitis and antibodies
to synaptic and neuronal cell surface proteins. Neurology. 2011 Jul;77(2):
179-89.
Downloads
Published
03-04-2020
How to Cite
Sathornsumetee, S. . (2020). Neuro-Oncology: An Emerging Neurologic Subspecialty in Thailand. Siriraj Medical Journal, 63(5), 174–176. Retrieved from https://he02.tci-thaijo.org/index.php/sirirajmedj/article/view/241003
Issue
Section
Special Issue
License
Users are free to share, copy, and redistribute all articles published in the Siriraj Medical Journal (SMJ) in any medium or format as long as you follow the following terms:
- Attribution — You must give appropriate credit, provide a link to the material, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the publisher endorses you or your use.
- NonCommercial — You may not use the material for commercial purposes.
- NoDerivatives — If you remix, transform, or build upon the material, you may not distribute the modified material.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
